| In millions, except per share items | Jun-30-21 | Mar-31-21 | Sep-30-20 | Jun-30-20 | Jun-05-20 | Mar-31-20 | Mar-05-20 | Dec-31-19 |
| | 10-Q | 10-Q | 10-Q | 10-Q | 8-K | 10-Q | 8-K | 10-K |
| Revenues: | | | | | | | | |
| Revenue, net | | | 51.3 | 55.5 | | 60.2 | | 65.9 |
| Revenue, net growth | | | -23.0% | -16.6% | | -6.6% | | 0.0% |
| Costs and expenses: | | | | | | | | |
| Cost of revenues | | | 47.9 | 44.9 | | 43.6 | | 42.4 |
| Selling, general and administrative expenses | | | 23.3 | 21.8 | | 22.0 | | 20.8 |
| Impairment charges | | | | | | 8.4 | | |
| Product development and research expenses | | | 9.1 | 8.8 | | 9.6 | | 10.8 |
| Total costs and expenses | | | 88.7 | 83.9 | | 83.6 | | 73.9 |
| Operating loss | | | -37.4 | -28.4 | | -23.3 | | -8.0 |
| Operating margin | | | -72.8% | -51.2% | | -38.7% | | -12.2% |
| |
| Other income (expense): | | | | | | | | |
| Foreign currency exchange gain (loss) | | | 3.3 | -0.7 | | -2.3 | | -1.5 |
| Interest and other expense, net | | | | -13.4 | | -5.9 | | |
| Gain on debt restructuring | | | 10.0 | | | | | -0.9 |
| Change in the fair value of derivative liabilities | | | -1.5 | -5.8 | | -1.3 | | |
| Loss before income tax expense | | | -21.9 | -28.5 | | -18.1 | | -25.0 |
| Income tax (benefit) expense | | | 0.1 | 0.0 | | 0.1 | | 0.1 |
| Tax rate | | | | -0.1% | | | | -0.4% |
| Loss attributable to common shareholders | | | -21.9 | -28.5 | | -18.1 | | 0.0 |
| |
| Loss per share | | | | | | | | |
| Basic loss per share (in dollars per share) | | | ($7.72) | ($8.96) | | ($7.14) | | ($2.32) |
| Diluted loss per share (in dollars per shares) | | | ($7.72) | ($8.96) | | ($7.14) | | ($2.32) |
| |
| Weighted average shares of common stock outstanding: | | | | | | | | |
| Basic (in shares) | | | 17.7 | 17.6 | | 17.5 | | 29.6 |
| Diluted (in shares) | | | 17.7 | 17.6 | | 17.5 | | 29.6 |